FDA Approved: LEVETIRACETAM — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved BluePoint Laboratories' supplemental application for levetiracetam (ANDA 078993), approving a generic version of the anti-seizure medication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• LEVETIRACETAM (levetiracetam)

Snippet

SUPPL AP for LEVETIRACETAM (LEVETIRACETAM)